Myelodysplastic syndromes standardized response criteria: Further definition [1]

Blood

Volumn 98, Issue 6, 2001, Pages 1985-

  Cheson, Bruce D ^a   Bennett, John M ^a   Kantarjian, Hagop ^a   Schiffer, Charles A ^a   Nimer, Stephen D ^a   Löwenberg, Bob ^a   Stone, Richard M ^a   Mittelman, Moshe ^a   Sanz, Guillermo F ^a   Wijermans, Pierre W ^a   Greenberg, Peter L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN;

ANEMIA; BLOOD TRANSFUSION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL PROTOCOL; DISEASE COURSE; HUMAN; LETTER; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTE; THROMBOCYTE COUNT;

EID: 0035885957     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.6.1985     Document Type: Letter

References (8)

1. Raza A. Improve or abandon the standardized response criteria for myelodysplastic syndromes recommended by the International Working Group. Blood. 2001;98:251-252.
2. Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 2000;96:3671-3674.
3. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87:4990-4997.
4. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma: NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244-1253.
5. Negrin RS, Stein R, Doherty K, et al. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human G-CSF plus erythropoietin: evidence for in vivo synergy. Blood. 1996;87:4076-4081.
6. Hellström-Lindberg E, Ahlgren T, Begguin Y, et al. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood. 1998;92:68-75.
7. List AF, Brasfield F, Heaton R, et al. Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome. Blood. 1997;90:3364-3369.
8. Greenberg P, Cox C, Le Beau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-2088.